Troponins in Chest Pain Evaluation

Along with history and physical examination, measurement of cardiac troponins has become an essential component of cardiac workups and diagnosis.

​

Cardiac troponins have been available for clinical use since 1995, when the first cardiac troponin T (cTnT) assay was approved. Improved cardiac specificity, and especially improved sensitivity, has led to more accurate diagnoses of cardiovascular disease and syndromes, particularly after the introduction of high-sensitivity cardiac troponin (hs-cTn) assays.

​

Troponin Biology: Subunits and Isoforms

Troponin complex subunits (TnT, TnI, TnC)

Troponin is a protein complex consisting of three regulatory subunits:
     -Troponin T (TnT): attaches the troponin complex to the actin filament and binds the troponin–tropomyosin complex.

     -Troponin I (TnI): inhibitory subunit; anchors the troponin–tropomyosin complex by binding to actin and prevents actin–myosin interaction when intracellular calcium is insufficient.

     -Troponin C (TnC): calcium-binding subunit.

 

Troponin is present in skeletal and cardiac muscle; smooth muscle lacks troponin. Troponin is bound to tropomyosin, a long protein that lies along the actin filament. In the relaxed state, the troponin–tropomyosin complex occludes the myosin-binding site on actin. With depolarization and increased intracellular calcium, calcium binds to TnC, producing a conformational change and disengagement of TnI; actin–myosin binding then occurs and the sarcomere (and myocardium) contracts.

​

Troponin isotypes and cardiac specificity (cTnI vs cTnT)

Troponin exists in three distinct molecular forms (isotypes) corresponding to fast-twitch skeletal muscle, slow-twitch skeletal muscle, and heart tissue. These forms are structurally different, enabling immunologic distinction of cardiac troponin from skeletal troponin. Troponin C forms are identical in cardiac and skeletal muscle, while there are cardiac-specific forms of Troponin I and T: cTnI and cTnT.

​

Cardiac Specificity of cTnI and cTnT

cTnT and cTnI differ in amino acid sequence from skeletal isoforms and are encoded by unique genes.

 

cTnI: Only one isoform of cTnI has been identified, and cTnI is not expressed in healthy, regenerating, or diseased human or animal skeletal muscle. It is completely cardiac specific.

​

cTnT: cTnT isoform expression has been demonstrated in skeletal muscle of patients with muscular dystrophy, polymyositis, dermatomyositis, and end-stage renal disease. The cross-reactivity can be reduced/omitted with careful assay antibody selection. However, false-positive (noncardiac) cTnT results can occur.

​

Intracellular Troponin Distribution: Bound vs Cytosolic Pool

In cardiomyocytes, troponins exist as a large structural (bound) pool (most of the protein, bound within the contractile apparatus), and a smaller free cytosolic pool. 4–10% of cTn is free in the cytosolic pool and the rest exists as bound to myofilaments.

​

These distributions explain the typical biphasic release pattern after cardiomyocyte injury: an early surge from cytosolic release, followed by slower ongoing release from the decaying contractile apparatus.

​

Historical Biomarkers Before Troponin

Before troponin, multiple biomarkers were used to identify myocardial injury.

 

In the 1960s and 1970s, biomarkers such as AST, LDH, and CK were used but were later abandoned due to lack of cardiac specificity.

 

More cardiac-focused markers such as CK-MB and LDH 1+2 followed, but still had an unacceptably high false-positive rate.

Troponins were first identified in 1965, but a reliable immunoassay for blood detection was not developed until the late 1990s.

 

Troponin testing has very high sensitivity once enough time has elapsed from symptom onset, and serial troponin testing is incorporated into the Fourth Universal Definition of Myocardial Infarction.

​

Why Troponin Rises: Myocardial Injury and Definitions

Pathophysiology of troponin release

Myocardial infarction occurs when coronary blood flow is blocked, producing a mismatch where oxygen supply does not meet oxygen demand, leading to necrosis and cell death. Cell membrane disruption allows intracellular contents to enter extracellular space and then the bloodstream. Troponin becomes detectable if released in sufficient quantities.

 

A basal amount of troponin is present in healthy individuals due to normal cardiac myocyte turnover. Troponin indicates pathophysiologic myocardial injury when the measured value exceeds the 99th percentile of the normal range (about three standard deviations above the mean).

​

Fourth Universal Definition of MI: chronic myocardial injury vs acute injury

According to the Fourth Universal Definition of Myocardial Infarction:

     -Myocardial injury: any cTn value >99th percentile upper reference limit (URL).

     -Acute myocardial injury: injury is considered acute if there is a rise and/or fall in cTn values.

​

Neither the Fourth Universal Definition nor European or American ACS guidelines specify a single time window for assessing an acute rise/fall; they simply require a dynamic change on serial troponin measurements to classify the injury as acute. Troponin dynamics are typically assessed at 0 and 1–3 hours (high-sensitivity assays) or 0 and 3–6 hours, but if a patient presents late near the troponin peak (in this scenario, the first troponin is often very high and ACS may be evident even without a clear dynamic change), the change may only become apparent on a later sample, even around 24 hours later.

​

Troponin Kinetics in Blood (Rise, Peak, and Clearance)

Troponin levels typically start to rise within 2–3 hours of chest pain onset. The Tn levels rise until peak, which is generally at 12 to 48 hours. Troponin levels then return toward normal over 4 to 10 days.

​

This expected rise-and-fall pattern helps distinguish evolving myocardial infarction from other causes of troponin elevation.

 

The actual plasma half-life of cTnI and cTnT is ~2 hours. Because troponin continues to be released from the bound pool within the contractile apparatus of the necrotic myocardium, the apparent half-life is ~24 hours, with cTnT slightly longer.

​

Chest pain duration vs troponin positivity: why symptom length is an imperfect predictor

Pain duration does not map cleanly to troponin release, because troponin rises with myocardial injury/necrosis (or other myocyte injury mechanisms), not with ischemic symptoms per se. Ischemia without cell death (angina, including unstable angina) can cause substantial chest pain with normal troponin.

 

A pathology review summarizes that reversible injury predominates for ~15 minutes, followed by a transition toward irreversible injury over ~20–60 minutes in severely ischemic myocardium.

 

So, a single ~15-minute episode is less likely to produce troponin >99th percentile, whereas ≥20–60 minutes of severe ischemia is more compatible with developing injury that can drive a diagnostic troponin rise.

​

Guideline context for symptom duration:

NICE (UK) flags ACS-suggestive symptoms as including chest/associated pain lasting >15 minutes.

AHA/ACC (US) emphasizes that anginal symptoms build over minutes and symptoms lasting only seconds are unlikely ischemic.

ESC notes that NSTE-ACS includes both NSTEMI (with myocardial necrosis) and unstable angina (ischemia without detectable myocyte injury), so substantial/prolonged ischemic symptoms can occur with normal troponin

 

Overall, troponin >99th percentile is more consistent with prolonged or repetitive severe ischemia (often >20–60 minutes in physiology terms), rather than a single brief episode.

​

High-Sensitivity Troponin (hs-cTn) Assays: Definition and Clinical Impact

High-sensitivity troponin testing was approved for clinical use in the U.S. in 2017. hs-cTn assays have high analytical sensitivity, with <10% imprecision at very low concentrations.

​

Analytical criteria for “high-sensitivity”

Analytical criteria for “high-sensitivity” (endorsed/refined by IFCC cardiac biomarker groups and aligned with AACC/IFCC statements) include:
     -Total imprecision (CV%) ≤10% at the 99th percentile URL, and

     -Ability to measure troponin above the assay’s limit of detection in at least 50% of healthy individuals.

​

4th vs 5th generation assays

CV% (coefficient of variation) describes how much an assay’s results vary when you repeat the same test. Lower CV% means better precision.

 

“Fifth-generation” hs-cTnT/hs-cTnI assays: CV% <10 at the 99th percentile URL.

“Fourth-generation” assays: CV ~10–20% at the 99th percentile URL.

​

Assay Standardization and Why Cutoffs Are Not Interchangeable

Why switching/comparing assays is difficult

Two major challenges limit switching and comparing between assays:

     -There is no primary reference cTnI material for manufacturers to standardize cTnI assays. Because of this there is no universal “gold-standard” troponin I reference sample to calibrate against, and different manufacturers’ assays are standardized differently. Thus, results and cutoffs aren’t directly interchangeable when you switch assays.

     -Measured concentrations vary because cTnI circulates in multiple forms; assays use antibodies targeting different epitopes, even within assays/instruments marketed by the same manufacturer.

 

Because each FDA-approved hs-cTn assay differs in sensitivity and reference populations, 99th percentile URL cutoffs are assay-specific.

​

Switching between and comparing cTnI and cTnT results

Although cTnI and cTnT correlate to some extent, their numeric values can differ substantially in the same patient. cTnT readings are generally lower.

 

Among patients with impaired renal function, cTnT is more commonly elevated than cTnI with both conventional and high-sensitivity assays.

​

Clinical Interpretation of Troponin: Core Principles

Always interpret in clinical context. Elevated troponin should be evaluated using ECG, symptoms, timing, and possibly imaging.

 

Use troponin as a continuous value. Higher concentrations are more likely linked to acute MI.

​

Serial measurement and kinetics are central. A significant rise and/or fall strongly supports an acutely evolving cardiac injury, most commonly acute MI, whereas stable elevations can occur in many chronic cardiac and noncardiac states.

​

Pretest probability matters. The 99th percentile cutoff does not mean 1% of the population has myocardial damage. It is useful when applied to patients with high pretest probability of ACS. In low pretest probability settings, a positive troponin may be suggestive but is not diagnostic of a coronary event. “Rule-out panels” in very low-risk patients reduces positive predictive value.

​

hs-Troponin Sensitivity and Sensitivity Over Time After Symptom Onset

A single hs-cTn value >99th percentile URL is sensitive for myocardial infarction but not specific; diagnosis may require serial testing and clinical correlation.

 

A prospective NEJM cohort (Keller et al., 2009) using a sensitive TnI assay with the 99th percentile URL cutoff showed that the sensitivity for MI of a single admission sample increases with time from chest-pain onset:

     -81.1% within 3 hours

     -87.7% at 0–<6 hours

     -94.5% at 6–12 hours

     -100% at >12 hours.

Adding serial testing (repeat at 3 or 6 hours) increased detection to 100%.

In that cohort, the “delta” criterion for the repeat sample at both 3 hours and 6 hours was a relative change (rise or fall) of ≥30% from the admission value, with at least one value above the 99th percentile.

​

Practically, a troponin >99th percentile is often present by 6–12 hours (~95%) and becomes very sensitive later.

​

Positive Predictive Value (PPV) of Troponin >99th Percentile

The ACC 2022 Expert Consensus highlights that how you “rule in” matters. In early studies, using hs-troponin rule-in zone (i.e., markedly elevated values (5x URL) and/or a significant rise/fall on repeat testing) produced a higher positive predictive value (around ~75%) for MI. In contrast, using only a single result above the 99th percentile as the rule-in threshold yielded a much lower PPV (around ~50%) in typical ED cohorts being evaluated for possible ACS (presentation maybe chest pain, dyspnea, syncope etc.).

 

In unselected emergency-department suspected-ACS populations, a troponin result above the 99th percentile URL has only modest PPV for type 1 MI, because many patients have non–type 1 MI myocardial injury (e.g., type 2 MI or chronic injury).

​

Wereski et al. (Circulation 2021) studied a large ED cohort of consecutive patients in whom the clinician suspected ACS and ordered troponin (High-STEACS trial population).

Presenting symptoms were (primary symptom was recorded in 87%):

• Chest pain: 81.6% (33,319/40,844)

• Dyspnoea: 4.8% (1,977/40,844)

• Syncope: 5.7% (2,332/40,844)

• Palpitations: 3.0% (1,213/40,844)

• Other: 4.9% (2,003/40,844)

A troponin concentration above the uniform 99th percentile at presentation had a PPV of 48% for type 1 MI. Using higher “rule-in” thresholds improved PPV only slightly (e.g., 5× URL: 62%).

Within diagnoses, chest pain dominated type 1 MI presentations (89.8%). They performed a chest-pain subgroup analysis. In that chest-pain subgroup, they report:

• 64 ng/L (=URL): PPV 72%, specificity 98%

• 5× URL: PPV 75%, specificity 99%

They note that no threshold achieved PPV ≥90% even in this chest-pain subgroup. 

​

Earlier emergency-department chest-pain data (APACE; Reichlin et al., Arch Intern Med 2012) also show why PPV varies: >99th percentile elevations were common outside AMI (e.g., present in unstable angina and other cardiac/noncardiac diagnoses), which lowers PPV in mixed populations.

​

hs-cTn Sampling Algorithms (ESC, AHA/ACC, ACEP) and Timing Caveats

ESC algorithm preferences (NSTE-ACS/ACS guidance)

ESC 2020 NSTE-ACS guideline favors the ESC 0/1-hour algorithm, with later sampling (e.g., 2 or 3 hours) as reasonable alternatives.

​

In the ESC 2020 guidance, the 0/3-hour protocol was downgraded to Class II, while 0/1-hour and 0/2-hour algorithms are Class I recommendations.

 

ESC 2023 recommends that if two hs-cTn measurements in a rule-in/rule-out pathway are inconclusive or the patient falls in the “observe” group, and no alternative diagnosis is found, obtain a third measurement at 3 hours.

​

ESC 0/1-hour diagnostic algorithm:

• Rule-out if symptom onset is > 3 hours and the initial value is very low

• Rule-out if the initial value is low and the 1-hour change lacks a relevant increase within 1 h (no 1 hΔ)

• Rule-in if the initial value or the 1-hour value is high

• Rule-in if the initial value changes within 1 hour by "1h delta"

• All others to the observation group (observe), repeat hs-cTn 3rd time at 3–6 hours and reassess for a dynamic rise/fall

​

​

​

​

​

​

​

​

​

​

​​

​

​

​

​​​​​​

​

ESC 0/2-hour diagnostic algorithm:

• Rule-out if symptom onset is > 3 hours and the initial value is very low

• Rule-out if the initial value is low and the 2-hour change lacks a relevant increase within 2 h (no 2 hΔ)

• Rule-in if the initial value or the 2-hour value is high

• Rule-in if the initial value changes within 2 hours by "2h delta"

• All others to the observation group (observe)​​, repeat hs-cTn 3rd time at 3–6 hours and reassess for a dynamic rise/fall

​

​

​

​

​

​

​

​

​

​

​

​

​

​​​​​

 

AHA/ACC guidance

The 2021 AHA/ACC guideline does not differentiate between these algorithms and recommends repeat hs-cTn sampling at 1, 2, or 3 hours and 3 to 6 hours for conventional troponin assays from ED arrival for AMI rule-out.

​

High-STEACS pathway (as summarized in the 2022 ACC ED chest pain consensus)

In ACC’s description of High-STEACS, MI can be ruled out at presentation when hs-cTnI <5 ng/L or hs-cTnT <6 ng/L, if >3 hours from symptom onset (and appropriate clinical/ECG context).

​

If the initial troponin is ≥5 ng/L but still below the 99th percentile, repeat at 3 hours. Rule-out at 3 hours requires both:

• the value remains <99th percentile, and

• the 0→3 h change is <3 ng/L.
   

If the delta is ≥3 ng/L (even if values remain below the 99th percentile), the patient is not safely ruled out and typically proceeds to additional testing (often a 6-hour sample) and continued evaluation.

 

High-STEACS uses sex-specific 99th percentile cutoffs, so “<99th percentile” is not a single universal number.

 

High-STEACS was derived and validated using Abbott ARCHITECT STAT hs-cTnI. An HTA-style evidence review notes the 5 ng/L rule-out threshold has been validated for Abbott ARCHITECT hs-cTnI and also for Siemens ADVIA Centaur hs-cTnI and Siemens Atellica hs-cTnI in some cohorts.

Thus, High-STEACS cutoffs are not manufacturer-neutral; do not “convert” or transplant the 5 ng/L and Δ3 ng/L rules unless there is evidence/validation for your assay and your lab reports reliably at that range.

​

The pathway does not specify a separate 6-hour delta threshold—6-hour interpretation is based on whether values cross the sex-specific 99th percentile and whether a clear rise/fall pattern supports acute myocardial injury in clinical context.

​

cTn Pathways on 2022 ACC Expert Consensus

​

​

​

​

​

​

​

​

​

​​

​

​

​

​

​

​

​

​

​

​​

​

​

​

​

​​

​

​

​​

​

​

​

​

ACEP policy

ACEP 2018 clinical policies suggest using a 0/2-hour approach to identify low-risk patients for more rapid ED discharge. ​This applies when the patient is pain free and has a non-ischemic ECG. An “inconclusive” delta should not be treated as a “negative” result.

​

Timing pitfalls

Rapid hs-cTn algorithms can fail in very early presenters (<2 hours) when hs-cTn may not have risen yet, and in late presenters (>12 hours) when a declining/stable pattern may be present.

​

Delta values are generally not applicable if symptoms occurred >12 hours prior to presentation: in late/very late MI, troponin may change little over short intervals, obscuring a clear rise/fall.

 

Interpretation in clinical context is necessary.

​

Proposed assay-specific “significant” absolute change at the 3rd sample (3–6 h)

ACC (2022 ED chest pain ECDP) notes that evidence-based hs-cTn delta thresholds at 3–6 hours are not established. A 20% relative change has been proposed but lacks specificity at low hs-cTn values. Therefore, near the sex-specific 99th percentile URL, ACC advises using assay-specific absolute (ng/L) deltas, whereas at higher hs-cTn values a ~20% relative change (compared to the first sample) may be reasonable; clinical judgment is required to interpret small fluctuations.

​

ESC Working Group (in the context of the older ESC 3-hour pathway) guidance has used a heuristic of >50% of the 99th percentile URL at 3 hours when the initial value is ≤99th percentile (or >20% when the initial value is >99th percentile), but this is consensus-based and assay/context dependent, not a universal 3–6 h absolute delta standard.

​

Below are published absolute-change cut-points at ~3 h when available and a “percent to absolute” conversion at the assay’s sex-specific and/or unisex 99th URL. Note that ESC and most non-US labs use the unisex URL for all patients.

​

hs-TnT (Elecsys; Roche)
Published absolute Δ0→3h: “no rise by 7 ng/L” used as a (0/3-h) rule-out change criterion in APACE-style protocol descriptions.
99th URL (F/M): 9 / 17 ng/L
Unisex/overall 99th URL: 14 ng/L (OUS Elecsys hs-cTnT 18-min) or 19 ng/L (US Gen 5 STAT 9-min; sex-specific 14/22).

50% of URL (unisex): 7 / 9.5 ng/L

50% of URL (F/M): 4.5 / 8.5 ng/L

​​

hs-TnI (Architect; Abbott)
Published absolute Δ0→3h (AMI “rule-in” style ROC cut-point in one ED cohort): >16.2 ng/L at 3 h after presentation.
High-STEACS 0/3 pathway (rule-out criterion includes): Δ0→3h <3 ng/L (with 3-h value ≤99th).
99th URL (F/M): 16 / 34 ng/L
Unisex/overall 99th URL: 26.2 ng/L (OUS) or 28 ng/L (US; sex-specific 17/35).

50% of URL (unisex): 13.1 / 14 ng/L

50% of URL (F/M): 8 / 17 ng/L

​​

hs-cTnI (Centaur; Siemens)
No widely cited absolute Δ0→3h
99th URL (F/M): 40 / 58 ng/L
Unisex/overall 99th URL: 46.5 ng/L (serum) or 47.3 ng/L (heparin plasma).

50% of URL (unisex): 23.25 / 23.65 ng/L

50% of URL (F/M): 20 / 29 ng/L​

 

hs-cTnI (Access; Beckman Coulter)
Published absolute Δ0→3h: a 3-h delta cut-point >35 ng/L reported to meet a PPV performance benchmark
99th URL (F/M): 11 / 20 ng/L
Unisex/overall 99th URL: 17.5 ng/L (Li-heparin plasma; manufacturer listing) or 18.2 ng/L (serum; commonly reported listing).

50% of URL (unisex): 8.75 / 9.1 ng/L

50% of URL (F/M): 5.5 / 10 ng/L

​

hs-cTnI (Clarity; Singulex)
No widely cited absolute Δ0→3h
99th URL (overall, one ED study): 8.67 ng/L

50% of URL: 4.335 ng/L

​

hs-cTnI (Vitros; Clinical Diagnostics)
No widely cited absolute Δ0→3h
99th URL (F/M): 9 / 12 ng/L
Unisex/overall 99th URL : 11 ng/L (serum and Li-heparin plasma listings; male differs by specimen: 12 serum vs 13 Li-hep).

50% of URL (unisex): 5.5 ng/L

50% of URL (F/M): 4.5 / 6 ng/L

​

hs-cTnI (Pathfast; LSI Medience)
No widely cited absolute Δ0→3h
99th URL (F/M): 20 / 30 ng/L
Unisex/overall 99th URL: 27.9 ng/L (PATHFAST hs-cTnI / cTnI-II listing; sex-specific 20.3/29.7).

50% of URL (unisex): 13.95 ng/L

50% of URL (F/M): 10 / 15 ng/L

​

hs-cTnI (TriageTrue; Quidel)
No widely cited absolute Δ0→3h
99th URL (F/M): 14 / 26 ng/L
Unisex/overall 99th URL: 20.5 ng/L (sex-specific 14.4/25.7).

50% of URL (unisex): 10.25 ng/L

50% of URL (F/M): 7 / 13 ng/L

​​​

Non-MI Causes of Elevated Troponin (Differential Diagnosis)

Troponins can be elevated in many conditions; any process that injures cardiac muscle can release troponin into circulation.

 

The most common injury mechanism is oxygen supply–demand mismatch as in acute MI, but many other conditions can also cause mismatch or direct injury.

​

Oxygen supply–demand mismatch examples

Tachycardia: reduced diastolic time decreases coronary perfusion while oxygen demand rises.

​

Shock: low blood volume/poor perfusion can cause mismatch.

​

Non-ischemic myocardial injury examples

Blunt chest trauma / cardiac contusion: direct trauma can cause substantial myocardial injury. In a study of 333 blunt chest trauma patients, elevated troponin occurred in 144 (44%).

​

Myocarditis and infiltrative diseases such as sarcoidosis can elevate troponin.

​

Troponin elevations can occur with processes outside the heart; for example, elevations are frequently seen with acute stroke without evidence of coronary artery disease. A proposed mechanism is autonomic disruption with catecholamine surge affecting cardiomyocytes.

​

Broader differential list (non-MI troponin elevation)

Renal failure, sepsis, critical illness, chronic severe heart failure, arrhythmias (tachyarrhythmias, bradyarrhythmias, heart blocks), pulmonary embolism, stroke (ischemic or hemorrhagic), myocarditis, takotsubo cardiomyopathy, pericarditis, aortic dissection, cardiac surgery, post–cardiac surgery, resuscitation (CPR), defibrillation, cardiac contusion/trauma, endocarditis, infiltrative diseases (e.g., amyloidosis), hypertrophic obstructive cardiomyopathy (HOCM), burns, extreme exertion, medications, transplant vasculopathy, snake venom.

​

Population and outpatient associations

In general population studies, hs-cTn correlates strongly with left ventricular hypertrophy (LVH), while underlying CAD shows a weaker association.

​

In outpatient measurements, increased hs-cTn is associated with increased risk of future cardiovascular events.

​

Troponin in Chronic Kidney Disease (CKD): Interpretation Challenges and Practical Approach

CKD complicates AMI evaluation because many CKD patients have troponin levels above the 99th percentile without evidence of acute coronary disease. However, the incidence and prevalence of MI is high among patients with CKD and carries a worse prognosis than in patients with normal kidney function and thus it is important to suspect and recognize MI in this population.

​

Mechanisms of chronic troponin elevation in CKD

Mechanisms of chronic Tn elevation are not fully understood and are likely multifactorial: Coexistent coronary atherosclerosis, LVH, heart failure, and hypertension can contribute to elevation. Advanced kidney failure may also directly damage heart muscle, likely due to uremic toxins.

​

Clearance/fragment hypothesis: Full-length troponin is relatively large protein and often circulates as protein-bound/complexed forms, making direct glomerular filtration unlikely. However, troponin is extensively fragmented, and smaller proteoforms may be excreted through the kidneys. Many circulating troponin fragments remain immunoreactive and are detected by clinical troponin immunoassays (assay-epitope dependent). Troponin-derived peptides have been detected in urine, although in very low concentrations with highly sensitive methods. Evidence supporting the fragment hypothesis includes that troponin fragments in ESRD are smaller than those in ACS, yet both are detected by hs-cTnT assays.

 

In renal dysfunction, cTnT is more commonly elevated than cTnI.

​

Epidemiology and prognosis in advanced CKD/ESRD

Angiographic studies identify significant coronary disease in up to ~40–50% of dialysis patients.

​

AMI is often lethal in CKD; cardiovascular disease accounts for >50% of deaths in ESRD.

​

Elevations in both cTnT and cTnI are reported in asymptomatic CKD patients.

​

In one study, nearly 30% of asymptomatic dialysis patients had cTnT >100 ng/L (a cutoff used for myocardial damage in that report).

​

Diagnostic performance issues in CKD

A meta-analysis of 14 studies found that the specificity of troponin >99th percentile is drastically decreased in CKD.

​

Abnormal hs-cTn levels in CKD reduce specificity for MI for both hs-cTnT and hs-cTnI.

​

Practical approach in CKD

Serial hs-cTn measurements are essential. A lack of increase on serial testing makes AMI highly unlikely.

​

Troponin in CKD is often chronically elevated and relatively steady; a rise/fall pattern is more suggestive of acute cardiac injury.

​

One accepted recommendation is that a 20% change during serial testing suggests a cardiac cause, though supporting research is limited.

​

0h/2h algorithm performance in CKD (Knott et al.)

In an observational emergency-deparment cohort study of 1992 patients in whom clinicians ordered hs-TnT (with 25% CKD, 501 patients), the diagnostic performance of the 0 h / 2 h rule-in algorithm was inferior in CKD. The study was not limited to “classic chest-pain/suspected ACS” presentations so it was a real-world troponin-testing population.

For CKD patients:
hs-cTnT at 0 h >100 ng/L → PPV 53%

hs-cTnT at 0 h >300 ng/L → PPV 80%

2 h delta hs-cTnT ≥10 ng/L → PPV 66%

2 h delta hs-cTnT >20 ng/L → PPV 86%

2 h delta hs-cTnT >30 ng/L → PPV 88%

​

Interpreting Serial hs-cTn Changes (Delta): Absolute vs Relative

There are no universal consensus statements or universal guidelines defining what constitutes a clinically significant change in hs-cTn values. Debate persists on whether to use absolute or relative (percent) change, what the optimal interval is for detecting AMI, and there are emerging considerations about possible sex and racial/ethnic differences in clinically significant troponin deltas. In the ED, there is debate about the optimal timeframe to recheck hs-cTn after symptom onset for rule-out.

​

Why troponin kinetics and delta matter

Because hs-cTn often yields measurable values below the 99th percentile, the serial change (delta) becomes a central component of ACS assessment.

​

Troponin release kinetics reflect intracellular distribution: a small cytosolic pool drives early release, and the larger bound pool drives later, slower release from contractile apparatus breakdown.

​

Early delta studies

Apple et al. (2009) evaluated percent changes (≥10, ≥20, ≥30%) of hs-TnI measured at 0 h and approximately 6 h; a ≥30% change from baseline or second follow-up sample optimized diagnostic specificity in patients with symptoms concerning ACS.

​

Eggers et al. (2011) examined ≥20%, ≥50%, and ≥100% hs-TnI changes with serial sampling within the first 24 hours; they found ≥50% would have produced too many false negatives for ACS and proposed combining Universal Definition concepts with a ≥20% hs-TnI delta to differentiate acute vs chronic elevations.

​

Proposed “reasonable” delta definitions

Across studies, either a 20% relative change in hs-cTn or an absolute change of ≥50% of the 99th percentile value (e.g., ~7 to 9 ng/L with hs-TnT, depending on assay) have been deemed reasonable definitions of clinically significant change.

​

ACC expert/educational suggestion: Use an absolute change criterion when baseline hs-cTn is ≤99th percentile, and a relative change criterion when baseline hs-cTn is >99th percentile.

​

Each strategy does come with its drawbacks: Relative change can overestimate change when baseline values are low, and underestimate change when baseline values are high.

​

Absolute change depends on the assay and patient factors (baseline value, biology, clinical risk factors).

​

Absolute Delta vs Percent Change: Practical Examples and Common Pitfalls

Why percent change can mislead

Low baseline troponin → percent change can be overly sensitive
A modest absolute increase can appear as a large percentage rise (e.g., small fluctuations after strenuous exercise may produce large percent changes).

​

High baseline troponin → percent change can be insufficiently sensitive
If baseline is high (late-presenting MI, near peak/plateau), a clinically important absolute change may not reach a 20% rise because 20% of a large number is very large.

​

Illustrative ACS trajectories

Early ED presentation: 43 → 98 ng/L
Percent rise: (98−43)/43 = 127% (meets ≥20% criterion)
Absolute rise: +55 ng/L (meets ≥20 ng/L criterion)

​

Late/near-peak: 615 → 724 ng/L
Percent rise: (724−615)/615 ≈ 18% (fails ≥20% criterion)
Absolute rise: +109 ng/L (meets ≥20 ng/L criterion)

​

Practical implication: when baseline hs-cTn is high or presentation is late, relying on percent change alone can miss evolving MI because values may be near peak/plateau.

​

Why absolute change can mislead

High baseline troponin → absolute change can be overly sensitive
In chronically elevated states (notably end-stage kidney disease), small absolute fluctuations can trigger “rule-in” despite non-ACS etiologies.

​​

Low baseline troponin → absolute change can be insufficiently sensitive (in theory)
If an absolute delta threshold is set too high, early small changes from a low baseline could be missed (thresholds are often set low to mitigate this).​

​​​

SUMMARY: Interpreting hs-cTn changes (delta): a practical workflow

Definitions: myocardial injury vs acute injury

A cTn value above the 99th-percentile upper reference limit (URL) defines myocardial injury. Injury is acute when serial testing shows a rise and/or fall; neither the Fourth Universal Definition nor European or American ACS guidelines define a single time window, they just require a dynamic change. In practice, dynamics are often assessed at 0 and 1 to 3 hours with hs-cTn (or 0 and 3 to 6 hours with conventional assays). In late presenters near the peak, the first value may already be very high and a clear rise or fall may only appear on later sampling, sometimes even at 24 hours.

Sampling strategy: recommended intervals and timing traps

Use a validated pathway and be cautious at timing extremes. Rapid hs-cTn algorithms can fail in very early presenters (under 2 hours from symptom onset) before troponin rises, and in late presenters (over 12 hours) when levels may be stable or declining; delta values are generally not helpful if symptoms began more than 12 hours prior to presentation. ESC generally favors 0/1-hour or 0/2-hour algorithms, with 0/3-hour as an alternative and an additional 3-hour sample if results are inconclusive. The 2021 AHA/ACC guideline allows repeat hs-cTn at 1, 2, or 3 hours after ED arrival for AMI rule-out (and 3 to 6 hours for conventional assays). ACEP (2018) supports a 0/2-hour approach to identify low-risk patients for expedited ED discharge.

What a single hs-cTn can (and cannot) tell you

Cutoffs are assay-specific because FDA-approved hs-cTn assays differ in sensitivity and reference populations. A single hs-cTn above the 99th percentile is sensitive but not specific for MI; PPV at the 99th percentile is typically 50 to 60% in mixed ED cohorts, so serial sampling and clinical correlation are essential. In a prospective NEJM cohort using hs-TnI with the 99th percentile URL cutoff, the sensitivity of a single admission sample rose with time from chest-pain onset (81.1% within 3 hours, 87.7% at 0 to under 6 hours, 94.5% at 6 to 12 hours, and 100% beyond 12 hours); adding repeat testing at 3 or 6 hours increased detection to 100%.

Delta interpretation: relative vs absolute change

There is no universal delta definition. ACC notes that a relative change of 20% or more supports acute myocardial injury, but near the 99th percentile, absolute assay-specific deltas are preferred and 3 to 6 hour change thresholds are not universal or evidence-based. ESC pathways use assay-specific cutoffs and deltas which do not apply in many situations or lead to “observe” pathway. Expert reviews and medical literature describe heuristics for significant delta such as a 50% change relative to the 99th-percentile URL when values are near the 99th percentile and 20% when baseline is already above the 99th, but these are not universal guideline thresholds. An ACC educational suggestion is to use absolute change when baseline hs-cTn is at or below the 99th percentile and relative change when baseline is above the 99th.

Pitfalls and special case: chronic elevation and CKD

Percent change can miss evolving MI when baseline hs-cTn is high or the patient presents late near the peak/plateau. Absolute deltas can overcall ACS in chronic elevation states, especially end-stage kidney disease, where small absolute fluctuations may trigger a rule-in despite non-ACS causes. In CKD, hs-cTn remains very sensitive for AMI but specificity is reduced; serial trends are critical, and lack of a rise on serial measurements makes AMI unlikely. One commonly used (limited-evidence) recommendation in CKD is that a 20% change on serial testing suggests a cardiac cause.

In a real-world ED cohort (n=1992; CKD 25%, n=501) where clinicians ordered hs-cTnT, the 0 h/2 h rule-in algorithm performed worse in CKD. In CKD patients:
hs-cTnT at 0 h >100 ng/L → PPV 53%

hs-cTnT at 0 h >300 ng/L → PPV 80%

2 h delta hs-cTnT ≥10 ng/L → PPV 66%

2 h delta hs-cTnT >20 ng/L → PPV 86%

2 h delta hs-cTnT >30 ng/L → PPV 88%

​​​​